PharmacoEconomics - open · 2026
Estimating the Long-Term Clinical and Economic Impact of Universal Varicella Vaccination in Portugal Using a Dynamic Transmission Model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Burgess Colleen, Kujawski Stephanie A, Amorim Miguel, Lang John C
Аннотация
BACKGROUND: Varicella vaccination is not currently included in Portugal's childhood national immunization program. We modeled the clinical and economic impact of a two-dose universal varicella vaccination (UVV) program in Portugal.
METHODS: A dynamic transmission model was adapted to Portugal to assess the impact of UVV over a 50-year time horizon. Two two-dose UVV strategies (first dose at 12 months, second dose at 5 years) were compared to no vaccination. Clinical outcomes included varicella and herpes zoster incidence rates, cases, deaths, quality-adjusted life years (QALYs) lost, and varicella-related health care resource use. Costs were assessed from the payer perspective (direct costs of treatment) and societal perspective (direct costs plus indirect costs of lost workdays).
RESULTS: Both UVV strategies reduced total varicella cases by 79.4-85.3%, outpatient visits by 78.9-84.8%, and varicella hospitalizations by 69.3-71.3% compared to no varicella vaccination. Herpes zoster cases were reduced by 2.4-2.9%. These strategies resulted in the gain of 5977-6094 QALYs and cost savings of €12.0 million (M)-15.9M from the payer perspective and €84.2M-93.9M from the societal perspective.
CONCLUSIONS: A two-dose UVV program is estimated to substantially reduce the burden of varicella disease in Portugal and to be cost-saving from both the payer and societal perspectives.
METHODS: A dynamic transmission model was adapted to Portugal to assess the impact of UVV over a 50-year time horizon. Two two-dose UVV strategies (first dose at 12 months, second dose at 5 years) were compared to no vaccination. Clinical outcomes included varicella and herpes zoster incidence rates, cases, deaths, quality-adjusted life years (QALYs) lost, and varicella-related health care resource use. Costs were assessed from the payer perspective (direct costs of treatment) and societal perspective (direct costs plus indirect costs of lost workdays).
RESULTS: Both UVV strategies reduced total varicella cases by 79.4-85.3%, outpatient visits by 78.9-84.8%, and varicella hospitalizations by 69.3-71.3% compared to no varicella vaccination. Herpes zoster cases were reduced by 2.4-2.9%. These strategies resulted in the gain of 5977-6094 QALYs and cost savings of €12.0 million (M)-15.9M from the payer perspective and €84.2M-93.9M from the societal perspective.
CONCLUSIONS: A two-dose UVV program is estimated to substantially reduce the burden of varicella disease in Portugal and to be cost-saving from both the payer and societal perspectives.